MADRIGAL PHARMACEUTICALS INC (MDGL)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MDGL
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MDGL | President and Chief Executive Officer and Class II Director | 59 | ["More than 30 years of experience in the biopharmaceutical industry","Executive Vice President, Specialty Care of Sanofi","President, Sanofi North America","Senior Vice President, Global Franchise Head, Multiple Sclerosis, Oncology & Immunology, Sanofi Genzyme","Chief Commercial Officer of Avanir Pharmaceuticals, Inc.","President and CEO of Lycera Corp","Senior Vice President, U.S. Commercial for Biogen Inc.","Holds a B.A. in Molecular Biophysics and Biochemistry from Yale University","Holds an M.B.A. from Harvard Business School"] | [] | 2026 |
Biography sourced from the proxy statement filing.
President and Chief Executive Officer of Madrigal since September 2023. Possesses more than 30 years of experience in the biopharmaceutical industry. Executive Vice President, Specialty Care of Sanofi, a global pharmaceutical company, and President, Sanofi North America, where he led a global organization of approximately 10,000 employees across five specialty therapeutic areas and served as a member of the Sanofi Executive Committee, from 2017 to September 2023. Senior Vice President, Global Franchise Head, Multiple Sclerosis, Oncology & Immunology, Sanofi Genzyme, from 2016 to 2017. Global Franchise Head Multiple Sclerosis of Sanofi Specialty Care from 2011 to 2016. Chief Commercial Officer of Avanir Pharmaceuticals, Inc. from April 2011 to November 2011. President and CEO of Lycera Corp in 2010. Senior Vice President, U.S. Commercial for Biogen Inc. from 2001 to 2009. Mr. Sibold holds a B.A. in Molecular Biophysics and Biochemistry from Yale University and an M.B.A. from Harvard Business School. Qualifications We believe that Mr. Sibold is qualified to serve on our Board due to his extensive operating, commercial, transactional and senior management experience as a pharmaceutical executive leading major commercialization programs at pharmaceutical and biotechnology companies.